Cost Analysis of Voriconazole Versus Liposomal Amphotericin B for Primary Therapy of Invasive Aspergillosis among High-Risk Hematologic Cancer Patients in Brazil
Xue, M.; Gao, X.; Ferreira, C.N.; Stephens, J.M.; Haider, S.; Figueiredo Valente, M.L.; Charbonneau, C.
Value in Health 18(7): A820
2015
ISSN/ISBN: 1098-3015
PMID: 26534377
DOI: 10.1016/j.jval.2015.09.257
Accession: 057526468
PDF emailed within 0-6 h: $19.90
Related References
Helou, G; Gao, C; Xue, M; Tarcha, N; Charbonneau, C 2016: Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin For Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Lebanon Value in Health 19(7): A583-A584Thaqafi, A.A.; Xue, M.; Farahat, F.; Gao, X.; Wafy, M.H.; Fahti, M.; Ibrahim, A.; Charbonneau, C. 2015: Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin for Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Saudi Arabia Value in Health 18(7): A667
Ostermann, H.; Solano, C.; Jarque, I.; Garcia-Vidal, C.; Gao, X.; Barrueta, J.A.; De Salas-Cansado, M.; Stephens, J.; Xue, M.; Weber, B.; Charbonneau, C. 2014: Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain Bmc Pharmacology and Toxicology 15: 52
Calabro, A.A.; Follador, W. 2003: Cost effectiveness of voriconazole versus amphotericin B for primary therapy of invasive aspergillosis Revista Brasileira de Medicina 60(7): 528-535
Kontoyiannis, D.P.; Hachem, R.; Lewis, R.E.; Rivero, G.A.; Torres, H.A.; Thornby, J.; Champlin, R.; Kantarjian, H.; Bodey, G.P.; Raad, I.I. 2003: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies Cancer 98(2): 292-299
Hachem, R.Y.; Boktour, M.R.; Hanna, H.A.; Husni, R.N.; Torres, H.A.; Afif, C.; Kontoyiannis, D.P.; Raad, I.I. 2008: Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy Cancer 112(6): 1282-1287
Kirkpatrick, W.R.; Coco, B.J.; Patterson, T.F. 2006: Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis Antimicrobial Agents and ChemoTherapy 50(4): 1567-1569
Pagano, L.; Valentini, C.G.; Fianchi, L.; Caira, M. 2011: Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? Journal of ChemoTherapy 23(1): 5-8
Grau, S.; Azanza, J.R.; Ruiz, I.; Vallejo, C.; Mensa, J.; Maertens, J.; Heinz, W.J.; Barrueta, J.A.; Peral, C.; Mesa, F.J.ús.; Barrado, M.; Charbonneau, C.; Rubio-Rodríguez, D.ío.; Rubio-Terrés, C. 2017: Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain Clinicoeconomics and Outcomes Research: Ceor 9: 39-47
Lewis, J.S.; Boucher, H.W.; Lubowski, T.J.; Ambegaonkar, A.J.; Day, D.L.; Patterson, T.F. 2005: Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis PharmacoTherapy 25(6): 839-846
Herbrecht, R.; Denning, D.W.; Patterson, T.F.; Bennett, J.E.; Greene, R.E.; Oestmann, Jörg-W.; Kern, W.V.; Marr, K.A.; Ribaud, P.; Lortholary, O.; Sylvester, R.; Rubin, R.H.; Wingard, J.R.; Stark, P.; Durand, C.; Caillot, D.; Thiel, E.; Chandrasekar, P.H.; Hodges, M.R.; Schlamm, H.T.; Troke, P.F.; de Pauw, B. 2002: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis New England Journal of Medicine 347(6): 408-415
Grau, S.; Antonio, J.M.; Soto, J.; Munoz, M.; Salas, E. 2003: Pin15 Cost-Effectiveness Analysis of Voriconazole Versus Amphotericin B in the Treatment of Invasive Aspergillosis in Spain Value in Health 6(6): 750-751
Caillot, D.; Thiébaut, A.; Herbrecht, R.; de Botton, S.ép.; Pigneux, A.; Bernard, F.éd.ér.; Larché, J.ér.ôm.; Monchecourt, F.ço.; Alfandari, S.; Mahi, L. 2007: Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial) Cancer 110(12): 2740-2746
Patterson, T.F.; Boucher, H.W.; Herbrecht, R.; Denning, D.W.; Lortholary, O.; Ribaud, P.; Rubin, R.H.; Wingard, J.R.; DePauw, B.; Schlamm, H.T.; Troke, P.; Bennett, J.E. 2005: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 41(10): 1448-1452
Chai, L.Y.A.; Kullberg, B.J.; Earnest, A.; Johnson, E.M.; Teerenstra, S.; Vonk, A.G.; Schlamm, H.T.; Herbrecht, R.; Netea, M.G.; Troke, P.F. 2014: Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis Plos one 9(2): E90176